FDA Approves Durvalumab/Chemo in dMMR Advanced Endometrial Cancer

News
Article

Data from the DUO-E trial support the FDA approval of durvalumab/chemotherapy for those with primary advanced or recurrent dMMR endometrial cancer.

Supporting data for the approval came from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200).

Supporting data for the approval came from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200).

The FDA has approved durvalumab (Imfinzi) in combination with carboplatin and paclitaxel followed by durvalumab maintenance for adults with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer, according to a press release from the agency.1

Supporting data for the approval came from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200).

Among 95 patients with dMMR tumors, the median progression-free survival (PFS) with durvalumab/chemotherapy was not reached (NR; 95% CI, NR-NR) vs 7 months (95% CI, 6.7-14.8) with chemotherapy alone (HR, 0.42; 95% CI, 0.22-0.80). Overall survival (OS) data were not yet mature at the time of the latest analysis.

Previous findings highlighted at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer showed a median PFS of 10.2 months (95% CI, 9.7-14.7) with durvalumab/chemotherapy in the intent-to-treat population compared with 9.6 months (95% CI, 9.0-9.9) for those who received chemotherapy only.2 The 1-year PFS rates were 48.5% vs 41.1%, respectively, and the 18-month rates were 37.8% vs 21.7%.

Frequent adverse effects associated with durvalumab plus chemotherapy in the DUO-E trial included nausea, peripheral neuropathy, musculoskeletal pain, alopecia, fatigue, and abdominal pain.

In the multi-center, double-blind, phase 3 DUO-E trial, patients with primary advanced or recurrent endometrial cancer and evaluable MMR status were assigned 1:1:1 to receive durvalumab plus chemotherapy, chemotherapy alone, or durvalumab plus chemotherapy and olaparib (Lynparza). Patients received durvalumab at 1120 mg or matched placebo every 3 weeks for up to 6 cycles followed by maintenance with durvalumab at 1500 mg every 4 weeks or placebo until progressive disease.

The trial’s primary end point was PFS per RECIST criteria. Secondary end points included OS, objective response rate, duration of response, and safety.

References

  1. FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer. News release. FDA. June 14, 2024. Accessed June 14, 2024. https://tinyurl.com/mvhx997f
  2. Chon HS, Thomas-Pepin J, Sundborg MJ, et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer (DUO-E/GOG-3041/ENGOT-EN10): objective response rate and duration of response by mismatch repair status. Presented at: SGO 2024 Annual Meeting on Women’s Cancer; March 16-18, 2024; San Diego, CA.
Recent Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.